Infrequent tumor initiative of the Children's Oncology Group: initial lessons learned and their impact on future plans.
The merger of the Pediatric Oncology Group, Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, and the National Wilms Tumor Study Group in 2000 offered the newly formed Children's Oncology Group (COG), an opportunity to study rare cancers that had not been the subject of organized evaluation within the context of a cooperative group. In 2002, the COG formed the rare tumor committee which is comprised of four subcommittees. This article details the experience of the infrequent tumor subcommittee for the period of 2002 to 2007. During the initial implementation of this strategy, we have observed low rates of registration within the COG registry and low levels of participation in open banking, biology, and first-line therapeutic studies. This initial experience has allowed us to develop alternative strategies to increase registration rates and clinical trial enrollments. It is hoped that these new plans will allow us to increase our ability to better understand the biology and improve the treatment outcome of young patients with infrequent cancers. Furthermore, our initial experience has demonstrated to us the potential power of expanded cooperation and collaboration at a global level.
Pappo
Alberto S
AS
St Jude Children's Research Hospital, Memphis, TN 38105, USA. alberto.pappo@stjude.org
Krailo
Mark
M
Chen
Zhengjia
Z
Rodriguez-Galindo
Carlos
C
Reaman
Gregory
G
D000293:Adolescent; D000328:Adult; D002648:Child; D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D012208:Rhabdomyosarcoma / Q000628:therapy; D018426:SEER Program